Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibodies Regulatory News (FAB)

Share Price Information for Fusion Antibodies (FAB)

Share Price is delayed by 15 minutes
Get Live Data
11.50    0.50 (4.55%)
Bid:
11.00
Ask:
12.00
Spread: 1.00 (9.091%)
Market Cap: £14.39m
FAB Live PriceLast checked at - London Stock Exchange

Intraday Fusion Antibodies Share Chart

Acquisition

30 Apr 2007 07:03

Fabian Romania Property Fund Ltd30 April 2007 Fabian Romania Property Fund Limited ("Fabian Romania" or the "Fund") Fabian Romania announces the purchase of a €60 million office building inBucharest Fabian Romania has reached agreement to purchase its fourth office project, theCubic office development (the "Cubic Centre"), in Bucharest. The Cubic Centrewill be a class A office building with a gross area of approximately 44,000square metres, located in North Bucharest. The building is being developed bythe Kendama, an experienced local developer in Romania. Construction hascommenced and completion is anticipated in the second quarter of 2009. The Cubic Centre will upon completion of construction provide a net lettableoffice area of 27,000 square metres over 12 floors, together with 533 carspaces. The building is located in a prominent location in the Pipera districtof North Bucharest and is likely to attract international tenants seeking classA office space. Vacancy rates for class A office space in in Bucharest are lessthan 3%. The acquisition is due to complete, subject to certain conditions, in twostages. The Fund will pay a first instalment of €12.25 million, of which €5million has already been paid in the form of a secured loan. At practicalcompletion of the building by the developer, the Fund will pay the finalinstalment based upon a forward purchase yield of 7.4% - 7.8% applied to rentsachieved. Based upon current rental estimates, the total value of thetransaction is estimated to be approximately of €60 million. The total equityrequirement for the fund is estimated to be €12 million. Commenting on the transaction, Mark Holdsworth, Managing Director of FabianCapital, the Investment Advisor to the Fund said: "We are delighted that the Fund has sealed its first investment since Admissionto AIM on favourable terms in what is a highly competitive market. The CubicCentre will provide a high quality addition to the Fund's portfolio of officebuildings. It will also give diversification geographically within the city bothin terms of building type and expected tenant mix." Mark Owen, Director responsible for acquisitions comments: "The new office development is in a prominent location in the rapidly expandingoffice location of the northern Pipera district of the City. This area will befurther enhanced by the new motorway link into the City. The Cubic Centre,which is already under construction on a fixed price basis, is well positionedto capitalise on the demand for Class A office space expected. We are already inearly discussions with a number of quality tenants seeking to upgrade theiroffice accommodation." The lead advisers on the transaction were Eurisko (property agent), WSP(technical advisers) and NNDKP (legal adviser). END For Comments:Fabian Romania:Mark Holdsworth +44 20 7499 9988 Nominated Adviser:Deloitte & Touche LLP +44 20 7936 3000James Lewis Broker:Shore Capital Stockbrokers LimitedDru Danford +44 20 7408 4090 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSExercise of share options and total voting rights
6th Dec 20217:00 amRNSHalf-year Report
2nd Dec 20217:00 amRNSUpdate on R&D
17th Nov 202110:00 amRNSNotice of Results
19th Oct 20214:25 pmRNSGrant of options
7th Oct 20214:40 pmRNSSecond Price Monitoring Extn
7th Oct 20214:35 pmRNSPrice Monitoring Extension
7th Oct 20212:06 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202111:06 amRNSSecond Price Monitoring Extn
7th Oct 202111:00 amRNSPrice Monitoring Extension
7th Oct 20217:00 amRNSNew contract win
27th Sep 20217:00 amRNSTotal Voting Rights
24th Sep 202112:00 pmRNSResult of AGM
24th Sep 20217:00 amRNSAGM Statement
1st Sep 20217:00 amRNSNotice of AGM
31st Aug 20215:00 pmRNSTotal Voting Rights
24th Aug 20217:00 amRNSCollaboration with Eurofins Discovery
10th Aug 20215:08 pmRNSExercise of Options and Total Voting Rights
10th Aug 20217:00 amRNSFinal Results
30th Jul 20215:00 pmRNSTotal Voting Rights
23rd Jul 20217:00 amRNSSuccessful milestone payment
29th Jun 20213:44 pmRNSHolding(s) in Company
28th Jun 20217:00 amRNSExercise of Options and Total Voting Rights
15th Jun 20217:00 amRNSHolding(s) in Company
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:36 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
28th May 20215:00 pmRNSTotal Voting Rights
21st May 20217:00 amRNSExercise of Options and Total Voting Rights
19th May 20212:06 pmRNSSecond Price Monitoring Extn
19th May 20212:01 pmRNSPrice Monitoring Extension
5th May 202112:20 pmRNSExercise of options
4th May 20217:00 amRNSTrading update
30th Apr 20212:05 pmRNSSecond Price Monitoring Extn
30th Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 20214:36 pmRNSPrice Monitoring Extension
31st Mar 20215:00 pmRNSTotal Voting Rights
25th Mar 20214:41 pmRNSSecond Price Monitoring Extn
25th Mar 20214:36 pmRNSPrice Monitoring Extension
25th Mar 20212:06 pmRNSSecond Price Monitoring Extn
25th Mar 20212:01 pmRNSPrice Monitoring Extension
10th Mar 20219:06 amRNSSecond Price Monitoring Extn
10th Mar 20219:00 amRNSPrice Monitoring Extension
8th Mar 20212:41 pmRNSExercise of Options and Total Voting Rights
26th Feb 20215:00 pmRNSTotal Voting Rights
16th Feb 20217:00 amRNSDirectorate Change
12th Feb 20219:05 amRNSHolding(s) in Company
22nd Jan 20213:37 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.